We look forward to welcoming you to the 8th annual U.S E-Cigarette Summit, which will take place in Washington D.C. on May 14, 2024.  We will be updating this site with the 2024 Agenda in due course.  The current agenda is from the 2023 event.

The video presentations from the 2023 Summit are now open access and can be viewed on the Agenda Page or by clicking HERE

The 2024 E-Cigarette Summit marks 60 years since the publication of U.S Surgeon General Luther Terry’s landmark report on smoking and health – a consensus document that unequivocally established the link between smoking and serious disease.  Viewed as the catalyst for the modern-day tobacco control movement, the 1964 report remains a historic example of the importance of science-led public health action.

The role of non-combustible alternatives to the cigarette is a variable that Surgeon General Terry and his committee did not have to address.  Determining whether and how to integrate such products into the fight against smoking-related death and disease is the task of public health and tobacco control experts of today. In this 60th Anniversary year, it is hoped that the 2024 Summit will embody the spirit of the 1964 report that placed scientific evidence at the forefront of public health action.

The E-Cigarette Summit has a single aim of facilitating respectful dialogue and thoughtful analysis of the independent scientific evidence to support policy and regulatory decisions.  U.S. smoking rates for both adults and youth have declined tremendously over the last 60 years, but of the 30 million Americans who still smoke today, it is those who are less privileged that bear the brunt of smoking-related deaths and diseases.  Much work remains to be done, if we are to achieve a smoke-free society for all, we hope that you can join us at the Summit in May.


The E-Cigarette Summit is hybrid and offers live and on-demand viewing option for those who are unable to join us in person. We aim to maximise the experience for everyone and all Summit participants will have access to the event app where they can view the Speaker slides, submit and answer questions and participate in the active chat/discussion.

We will “live stream” the Summit as per the agenda (US EST)  Individual videos of speaker presentations and the panel discussions will be added to the virtual platform within 48 hours of the live event for you to watch/re-watch later.  The app will be live for 3 months after the event.



Prof Thomas J. Glynn

Prof Thomas J. Glynn
Adjunct Lecturer, Stanford Prevention Research Center
Stanford University School of Medicine


Prof Robin J. Mermelstein, PhD

Prof Robin J. Mermelstein, PhD
Distinguished Professor of Psychology and IHRP Director
University of Illinois, Chicago


Deborah Arnott

Chief Executive

Action on Smoking and Health (UK)

Ben Youdan


ASH New Zealand

Alex Clark

Chief Executive Officer


Clive Bates


Counterfactual Consulting Ltd

Associate Prof Abigail Friedman

Associate Professor

Dept of Health Policy & Management, Yale School of Public Health

Dr. Nancy A. Rigotti, MD

Professor of Medicine, Harvard Medical School

Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

Tim Phillips

Managing Director


Dr Brian King

Director, Center for Tobacco Products (CTP)

Food and Drug Administration (FDA)

Professor Ann McNeill

Professor of Tobacco Addiction

Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

Dr Rafael Meza

Distinguished Senior Scientist

Integrative Oncology, BC Cancer Research Institute

Dr. Brian Yagi, M.D.,J.D.

Assistant Professor of Internal Medicine

Johns Hopkins School of Medicine

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

Prof Mike Cummings

Professor, Dep't Psychiatry & Behavioural Sciences

Medical University of South Carolina

Prof Benjamin A. Toll

Professor of Public Health Sciences & Psychiatry

Medical University of South Carolina

Prof Scott Sherman

Professor of Population Health, Medicine and Psychiatry

NYU Grossman School of Medicine

Assoc Prof Andrea Villanti

Associate professor in the Department of Health Behavior, Society, and Policy

Rutgers School of Public Health

Prof Ron Borland

Professor of Psychology - Health Behaviour

School of Psychology, Deakin University

Ruoyan Sun

Assistant Professor, Department of Health Policy & Organization

School of Public Health, University of Alabama at Birmingham

Prof Kenneth E. Warner

Avedis Donabedian Distinguished University Professor Emeritus and Dean Emeritus

School of Public Health, University of Michigan

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Centre, Stanford University School of Medicine

Mitch Zeller J.D

Retired Director, Center for Tobacco Products (CTP)

The Food & Drug Administration (FDA)

Martin Dockrell

Tobacco Control Programme Lead

The Office of Health Improvement and Disparities (OHID), UK

Dr Amanda L. Graham

Chief Health Officer

Truth Initiative

Prof Neal L. Benowitz MD

Professor of Medicine Emeritus (Active)

University of California, San Franciso

Prof Robin Mermelstein

Distinguished Professor of Psychology and IHRP Director

University of Illinois, Chicago

Dr Jamie Hartmann-Boyce

Assistant Professor in Health Promotion and Policy

University of Massachusetts Amherst


The E-Cigarette Summit provides an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics. The format includes high level briefings from global experts followed by panel discussions and audience Q&A.

  • If vaping Is a gateway to cigarette smoking, what are the implications?
  • Past and future trends in nicotine-delivery product use
  • Effects of reduced-risk nicotine products on smoking prevalence and cigarette sales
  • Flavored nicotine product sales restrictions in the US: Policy variations and impacts
  • Are e-cigarettes less addictive than cigarettes – why does it matter?
  • E-Cigarettes and smoking cessation – understanding the data
  • Evidence, emotions and philosophy – why all are important in tobacco control policy
  • The key differences and similarities of vaporized cannabis versus nicotine
  • Risk perception of e-cigarettes and vaping – the role of health communication
  • Interactions between cannabis and nicotine use
  • Policy comparisons between the US, Canada, UK and New Zealand – Who is doing what and why.
  • What doctors say…and what patients hear – should e-cigarettes be recommended for smoking cessation?
  • What can we learn from historical events and US per-capita cigarette data from 1984 to present?
  • E-cigarettes and mental health disorders: Opportunity or concern?
  • What constitutes success?  A dialogue on the “end state”


The E-Cigarette Summit is particularly relevant to:

  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders


  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders